Assembly BiosciencesASMB
ASMB
About: Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Employees: 73
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
88% more capital invested
Capital invested by funds: $30.4M [Q1] → $57.1M (+$26.7M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
1.12% less ownership
Funds ownership: 42.34% [Q1] → 41.23% (-1.12%) [Q2]
8% less funds holding
Funds holding: 37 [Q1] → 34 (-3) [Q2]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$50
95%
upside
Avg. target
$50
95%
upside
High target
$50
95%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio | 95%upside $50 | Buy Assumed | 18 Aug 2025 |
Financial journalist opinion
Based on 5 articles about ASMB published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts
Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients, with a 94% reduction in HSV-2 shedding and genital lesion rates. Upcoming catalysts include monthly dosing data for ABI-5366 and phase 1b data for ABI-1179, both expected in fall 2025, plus potential Gilead opt-in milestones. ASMB addresses a major unmet need, as no new HSV-2 therapies have been approved in 25+ years and the market could reach $4B by 2030.
Neutral
GlobeNewsWire
2 weeks ago
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599. Each pre-funded warrant will have a nominal exercise price of $0.001 per share of common stock and will be immediately exercisable. Each accompanying Class A warrant will have an exercise price of $21.60 per share of common stock, will be immediately exercisable and will expire on the earlier of (i) five years from the date of issuance (August 11, 2030) and (ii) the date that is 30 days after the public announcement that Assembly Bio has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. Each accompanying Class B warrant will have an exercise price of $21.60 per share of common stock, will be exercisable on or after November 15, 2026 and will expire on December 31, 2026, provided that each Class B warrant will automatically terminate in full and be extinguished and shall no longer be exercisable in the event that Assembly Bio publicly announces prior to November 15, 2026 that it has received at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreement.
Neutral
GlobeNewsWire
2 weeks ago
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period – – Favorable safety and tolerability profile observed in the first two cohorts evaluating weekly oral doses of ABI-5366 – SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim antiviral activity, clinical outcomes, safety and pharmacokinetic (PK) results from a Phase 1b study evaluating ABI-5366, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor, in participants seropositive for HSV type 2 (HSV-2) with recurrent genital herpes.
Neutral
GlobeNewsWire
2 weeks ago
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced interim data from several cohorts from the ongoing Phase 1a clinical trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
Neutral
GlobeNewsWire
2 weeks ago
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 –
Neutral
GlobeNewsWire
1 month ago
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –
Neutral
GlobeNewsWire
1 month ago
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b portion of the Phase 1a/b study of its long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate ABI-1179.
Neutral
GlobeNewsWire
2 months ago
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort –
Neutral
GlobeNewsWire
3 months ago
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
Negative
Zacks Investment Research
3 months ago
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago.
Charts implemented using Lightweight Charts™